Intravenous Ketamine reduces psychological pain in suicidal inpatients: A secondary analysis of a six-week randomized placebo-controlled trial.

Study at a glance

Characteristics	Secondary analysis of a randomized placebo-controlled trial Peer reviewed
Population	Suicidal inpatients
Intervention	Ketamine
Duration	Six weeks
Topics	Esketamine Ketamine
Key findings	Intravenous ketamine reduced psychological pain more than placebo in suicidal inpatients over six weeks, suggesting that alleviating psychological pain may contribute to ketamine's anti-suicidal effects.

Other randomized controlled trials on ketamine, most cited first.

Study	Year	Design	Participants
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Healthy human subjects recruited from the community	1994	Randomized controlled trial	n = 19
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial Patients with treatment-resistant major depression experiencing a major depressive episode	2013	Randomized controlled trial	n = 73
Remifentanil-induced Postoperative Hyperalgesia and Its Prevention with Small-dose Ketamine Patients undergoing major abdominal surgery	2005	Randomized controlled trial	n = 75
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder Patients with chronic PTSD related to a range of trauma exposures	2014	Randomized controlled trial	n = 41
Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers Healthy volunteers	2000	Single-blind placebo-controlled study	n = 20